Clinical Trial Update: CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 trial compares dose-adjusted mycophenolate mofetil (CellCept) with fixed-dose standard care in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Rabin Medical Center | Conditions: Renal Transplant | Phase 4 | Status: UNKNOWN